1	Augmenting electronic health record data with social and environmental determinant of
2	health measures to understand regional factors associated with asthma exacerbations
3	Alana Schreibman <sup>1</sup> , Kimberly Lactaoen <sup>1</sup> , Jaehyun Joo <sup>1</sup> , Patrick K. Gleeson <sup>2</sup> , Gary E.
4	Weissman <sup>1,2</sup> , Andrea J. Apter <sup>2</sup> , Rebecca A. Hubbard <sup>3</sup> , Blanca E. Himes <sup>1</sup>
5	
6	<sup>1</sup> Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine,
7	University of Pennsylvania, Philadelphia, PA 19104
8	<sup>2</sup> Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine,
9	University of Pennsylvania, Philadelphia, PA 19104
10	<sup>3</sup> Department of Biostatistics, School of Public Health, Brown University, Providence, RI 02912
11	
12	Corresponding author:
13	Blanca E Himes, PhD
14	402 Blockley Hall
15	423 Guardian Drive
16	Philadelphia, PA 19104
17	Phone: (215) 573-3282

18 Email: <u>bhimes@pennmedicine.upenn.edu</u>

#### 19 Abstract

20 Electronic health records (EHRs) provide rich data for diverse populations but often lack 21 information on social and environmental determinants of health (SEDH) that are important for 22 the study of complex conditions such as asthma, a chronic inflammatory lung disease. We 23 integrated EHR data with seven SEDH datasets to conduct a retrospective cohort study of 6,656 24 adults with asthma. Using Penn Medicine encounter data from January 1, 2017 to December 31, 25 2020, we identified individual-level and spatially-varying factors associated with asthma 26 exacerbations. Black race and prescription of an inhaled corticosteroid were strong risk factors 27 for asthma exacerbations according to a logistic regression model of individual-level risk. A 28 spatial generalized additive model (GAM) identified a hotspot of increased exacerbation risk 29 (mean OR = 1.42, SD 0.14, p < 0.001), and inclusion of EHR-derived variables in the model 30 attenuated the spatial variance in exacerbation odds by 33.8%, while additionally adjusting for the SEDH variables attenuated the spatial variance in exacerbation odds by 67.2%. Additional 31 spatial GAMs adjusted one variable at a time revealed that neighborhood deprivation (OR = 32 33 1.05, 95% CI: 1.03, 1.07), Black race (OR = 1.66, 95% CI: 1.44, 1.91), and Medicaid health 34 insurance (OR = 1.30, 95% CI: 1.15, 1.46) contributed most to the spatial variation in 35 exacerbation odds. In spatial GAMs stratified by race, adjusting for neighborhood deprivation and health insurance type did not change the spatial distribution of exacerbation odds. Thus, 36 while some EHR-derived and SEDH variables explained a large proportion of the spatial 37 38 variance in asthma exacerbations across Philadelphia, a more detailed understanding of SEDH variables that vary by race is necessary to address asthma disparities. More broadly, our findings 39 40 demonstrate how integration of information on SEDH with EHR data can improve understanding 41 of the combination of risk factors that contribute to complex diseases.

#### 42 Author summary

43 Electronic health records constitute an important source of data for understanding the health of large and diverse real-world populations, however, they do not routinely capture socioeconomic 44 45 and environmental factors known to affect health outcomes. We show how electronic health 46 record data can be augmented to include individual measures of air pollution exposures, 47 neighborhood socioeconomic status, and the natural and built environment using patients' 48 residential addresses to study asthma exacerbations, episodes of worsening disease that remain a 49 major public health challenge in the United States. We found that on an individual patient-level, 50 Black race and prescription of an inhaled corticosteroid were the factors most strongly associated 51 with asthma exacerbations. In contrast, neighborhood deprivation, race, and health insurance type accounted for the most spatial variation in exacerbation risk across Philadelphia. Our 52 53 findings provide insight into factors that contribute to asthma disparities in our region and present a framework for future efforts to expand the scope of electronic health record data. 54

#### 56 Introduction

57 Electronic health records (EHRs) are a source of rich patient-level data for large and diverse 58 populations that can be used for research due to their widespread availability [1]. However, EHR 59 data often contain incomplete or low-quality measures of social and environmental determinants 60 of health (SEDH), limiting their utility for the study of complex diseases [2]. Recent efforts to 61 address this limitation have included developing methodologies to integrate external data on the 62 physical, built, and social environment via linkage with patient addresses [3-5], with high-63 resolution geospatial datasets providing the closest estimate of individual exposures [6]. 64 Integrated EHR and SEDH datasets can be used to understand both individual-level outcomes 65 and patterns of risk across a spatial region, thereby providing insights for both precision 66 medicine and precision public health efforts. Because many environmental exposures pose a 67 greater risk to select groups of people, integrating external information on SEDH with EHR data is also helpful to address health disparities according to race, ethnicity, and socioeconomic 68 69 status.

70 Asthma, a chronic disease that is characterized by inflammation and reversible narrowing 71 of the airways, affects over 25 million people or approximately 8% of the United States 72 population [7]. Racial and ethnic disparities in its morbidity and mortality are well known, and 73 those living in poverty are also more likely to have asthma [7–11]. The clinical goals of asthma 74 management are to control patients' symptoms and minimize long-term risk of lung function 75 decline [12]. This includes preventing asthma exacerbations, episodes of worsening disease 76 which require treatment with systemic steroids [13]. However, despite guideline-directed clinical management, asthma exacerbations remain common, contributing to asthma-related morbidity 77 78 and mortality as well as higher health care costs and utilization [14,15]. Risk factors for asthma

exacerbations in adults include female sex [16], obesity [17], current or past smoking [18],

80 comorbid allergic rhinitis or chronic obstructive pulmonary disease (COPD) [17,19], and a history of previous exacerbations [20]. Observational studies have also found independent 81 82 associations between asthma exacerbations and exposure to particulate matter (PM), gaseous air 83 pollutants, and to mixtures of pollutants such as traffic-related air pollution (TRAP) [21]. 84 Similarly, associations between asthma exacerbations and living in poverty [22], substandard 85 housing conditions, such as the presence of mold and pests [23,24], and neighborhood "greenness" [25,26] have been documented. 86 87 Because asthma exacerbations result from complex interactions among various 88 biological, social, and environmental factors that vary across individuals and geographically, 89 creating generalizable models of exacerbations remains an unachieved goal. Further, because in 90 the United States there is a high correlation between minoritized race or ethnicity, poverty, and 91 harmful environmental exposures, disentangling relationships among key variables is difficult 92 [9,27]. Approaches that model many asthma-related variables in specific regions may lead to the 93 identification of actionable strategies to reduce exacerbations locally, and using EHR data to 94 create these models has the advantage of providing health information for the specific catchment 95 region served by a given healthcare system. Few studies have linked EHRs with a diverse set of 96 SEDH variables to study asthma exacerbations using patient-level data [28–30], and to our 97 knowledge, none have used geospatial analysis techniques to understand the contribution of 98 these factors to the spatial distribution of exacerbation risk. Here, we show how EHR data can be 99 extended to include individualized measures of air pollution exposures, socioeconomic status 100 indices, and measures of the natural and built environment to identify local factors associated 101 with asthma exacerbation risk.

5

### 102

#### 103 Methods

A retrospective cohort analysis was performed using de-identified EHR data from Penn
Medicine, a large health system that serves the greater Philadelphia area, from encounters dated
1/1/2017-12/31/2020. Our study was approved by the University of Pennsylvania Institutional
Review Board (IRB) under protocol number 824789. An overview of our study design is shown
in Fig 1.

109

110 <u>Study population</u>

111 Patient-level encounter data was obtained for adults (i.e.  $age \ge 18$  years) who had at least one 112 encounter with an International Classification of Diseases (ICD)-10 code for asthma (J45\*) and 113 who were prescribed a short-acting  $\beta_2$ -agonist (SABA) (S1 Table). The most recent residential 114 address for each patient was obtained and geocoded using previously described methods [3]. 115 Demographic, comorbidity, and medication data for encounters during the study period was 116 extracted and used to compute several variables, hereafter referred to as "EHR-derived 117 variables." These included: age at first encounter, sex, race, ethnicity, body mass index (BMI), 118 health insurance type, smoking status, chronic obstructive pulmonary disease (COPD), allergic 119 rhinitis, a modified Elixhauser score [31], inhaled corticosteroid (ICS) prescription, and years 120 followed (defined as the number of years between first and last encounter). Additional details, 121 including inclusion and exclusion criteria and definitions of the EHR-derived variables, are 122 provided in S1 Text.

123

124 <u>Outcome</u>

125 Asthma exacerbations were defined as encounters with an oral corticosteroid (OCS) prescription 126 (S1 Table) and either 1) a primary asthma diagnosis code (ICD-10, J45\*) for encounters with 127 primary diagnosis codes listed or 2) a nonprimary asthma ICD-10 code for encounters without a 128 primary diagnosis listed but only one or two ICD-10 codes listed. A count of exacerbations 129 during the study period was computed for each patient. 130 131 SEDH data 132 Seven external datasets were integrated with our EHR dataset via linkage with patient geocodes, 133 creating variables that are hereafter referred to as "SEDH variables." Additional details on data 134 processing are reported in S1 Text, and dataset sources and spatiotemporal dimensions are 135 summarized in S2 Table. All processed SEDH data is available in Sensor-based Analysis of 136 Pollution in the Philadelphia Region with Information on Neighborhoods and the Environment (SAPPHIRINE), a web application that integrates spatially distributed high-resolution social and 137 environmental data in the greater Philadelphia region to facilitate the conduct of local health 138 139 studies [32].

140

#### 141 *Air pollution exposures*

Average pollutant exposures were assigned to each patient using high-resolution (~1x1 km<sup>2</sup>) geophysical model estimates. 2017-2019 NO<sub>2</sub> estimates (in parts per billion by volume, or ppbv) and 2017-2020 PM2.5 estimates (in  $\mu$ g/m<sup>3</sup>) were downloaded from resources reported in Cooper et al. and van Donkelaar et al., respectively, temporally averaged, and linked to the study cohort using bilinear interpolation [33,34]. Exposure to other toxic airborne chemicals from point sources was estimated using the EPA Toxic Release Inventory (TRI) [35]. Total toxic air release

148	exposure by patient was computed as the sum of toxic releases (in kilograms) over the study
149	period within a 1-km circular buffer of each patient's residential address. Exposure to air
150	pollution from mobile sources was estimated as the sum of the daily vehicle distance traveled
151	(DVDT), a metric computed using traffic data published by the Pennsylvania Department of
152	Transportation, within a 300-m circular buffer [36].
153	
154	Neighborhood socioeconomic environment
155	Socioeconomic disadvantage for each person was summarized as the Area Deprivation Index
156	(ADI), a validated index computed for each Census block group based on several ACS variables

157 [37]. A higher ADI score indicates greater disadvantage. 2018 ADI data was extracted from the

158 Neighborhood Atlas and was assigned to each patient by block group [38].

159

#### 160 Built and natural environment

161 Asthma-related housing code violation data (i.e. pests, water damage, and indoor air 162 contamination) was obtained from a Philadelphia Department of Licenses and Inspections 163 dataset reported by OpenDataPhilly (S3 Table) [39]. For each block group, the number of 164 violations during the study period per 100 people (based on the 2019 ACS population estimates) 165 was computed and assigned to each patient. Vegetation density was summarized as the 166 normalized difference vegetation index (NDVI), an index with values ranging from -1.0 to 1.0 167 where higher positive values represent higher vegetation density. NDVI was computed in Google 168 Earth Engine using surface reflectance images from the Landsat 8 satellite during the study 169 period and assigned to each patient as the mean value within a 300-m circular buffer [40].

#### 171 <u>Statistical analysis</u>

172 Analyses were conducted in R 4.2 [41].

173

174 *Study area* 

175 To minimize bias in our geospatial analyses introduced by uneven spatial density across the Penn 176 Medicine catchment area, we restricted our study region to spatial areas in which the geospatial 177 representativeness of our EHR cohort was adequate compared to the underlying population. 178 Following methods described in Xie et al. [42], we computed a spatial representation ratio 179 (SRR), defined as the ratio between the proportion of our EHR cohort living in each census 180 block group and the proportion of the Philadelphia population living in that block group, as 181 reported by the 2019 American Community Survey (ACS). We defined our study region as 182 contiguous census tracts (i.e. adjacent or separated by a non-residential area such as a park) with 183 a mean SRR of 0.5 or greater. Only patients who resided in this study region were included in 184 analyses.

185

#### 186 Modeling individual-level risk factors

187 Chi-squared and Kruskal-Wallis rank sum tests were used in bivariate analyses to assess 188 associations between patient characteristics and asthma exacerbation level (i.e. 0, 1-2, 3-4, 5+) 189 during the study period, and to compare the characteristics of complete cases to individuals with 190 missing data. To identify patient-level factors associated with asthma exacerbations, we fit 191 logistic regression models with asthma exacerbations as a binary case-control (0 vs >0) outcome. 192 This approach was chosen to match the dichotomous outcome used in spatial analyses. Logistic 193 regression models were initially adjusted for EHR-derived variables only, and then adjusted for

194 both EHR-derived and SEDH variables (EHR & SEDH-adjusted). Years followed was included 195 as a covariate in both models to account for variation in the length of available follow-up across 196 patients. Model fit was assessed using the Akaike information criterion (AIC). We checked for 197 multicollinearity by computing Pearson's correlation coefficients between all EHR and SEDH 198 variables, while selecting White race and Private health insurance type as reference levels for the 199 two nominal categorical variables, and we computed variance inflation factors (VIF) for all 200 independent variables. 201 202 Sensitivity analysis for individual-level risk factors 203 We conducted sensitivity analyses of individual-level risk factors by fitting negative binomial 204 regression models with asthma exacerbations represented as a count outcome and comparing 205 results to those of logistic regression models. The negative binomial regression models were 206 adjusted first for EHR-derived variables only and then for EHR & SEDH variables, while 207 including years followed as an offset in each model. 208 209 Modeling spatial risk factors 210 To estimate local odds of exacerbation as a function of location, spatial generalized additive 211 models (GAMs) were fit with a binary case-control outcome (0 vs >0 exacerbations) on a grid of points across the study region, using the R MapGAM package and previously described methods 212 213 (S1 Text) [3,43]. Maps of spatial effect predictions were created for the smoothed spatial term of 214 each model, where the spatial odds ratio (OR) at each point represented the ratio between the 215 odds of exacerbation at that point and the median odds across all points. First, a univariable

model adjusted only for years followed, hereafter referred to as "unadjusted model", was fit to

217 identify hotspots and coldspots across the study region. Next, multivariable models adjusted for 218 1) only EHR-derived variables and 2) EHR & SEDH variables were compared to the unadjusted 219 model by computing the mean and standard deviation (SD) of the spatial ORs at points within 220 any overlapping hotspots, and by computing the percent difference between the variance in ORs 221 across the full study region in the adjusted models and the unadjusted model. To understand the 222 contribution of individual variables to the observed spatial effects, we fit additional models 223 adjusted for each EHR-derived or SEDH variable one variable at a time (all models were also 224 adjusted for years followed) and computed the percent difference between the variance in ORs in 225 these models and the unadjusted model. Model fit was assessed using the AIC. 226 227 Stratified analysis 228 We conducted a stratified analysis to further evaluate the association between race and asthma 229 exacerbations. Chi-square and Wilcoxon rank sum tests were used to assess bivariate relationships between race and other variables. To test whether any EHR or SEDH variables that 230 231 were correlated with race influenced spatial patterns of asthma exacerbation risk independently 232 of race, spatial GAMs adjusted one variable at a time were fit on each race stratum using the 233 same approach described above. Before fitting the models, SRR selection was repeated for each 234 stratum to account for the uneven geographic distribution of race across the initial study region. 235 236 **Results** 237 Following selection of patients based on inclusion/exclusion criteria and spatial filtering (S1 Fig), the retrospective study cohort consisted of 6,656 asthma patients, 2,329 of whom had one 238 239 or more exacerbations (Table 1), with residence in 249 census tracts in Philadelphia (S2 Fig).

240 The spatial distribution of all processed SEDH datasets within the study region is shown in S3 241 Fig. The EHR-derived variables years followed, age, race, BMI, health insurance type, smoking 242 status, COPD, allergic rhinitis, Elixhauser comorbidity score, and ICS, as well as the SEDH 243 variable ADI were the most significantly associated with exacerbations according to bivariate 244 analyses (p < 0.001) (Table 1). Patients with more exacerbations during the study period were 245 followed for more years, more likely to be aged 35-54, of Black race, or class 2 or class 3 obese, 246 and more likely to have Medicaid health insurance, a history of smoking, COPD, allergic rhinitis, 247 higher Elixhauser comorbidity scores, an ICS prescription, or live in neighborhoods with higher 248 ADI. The proportion of patients in the study cohort who were prescribed controller medications 249 including ICS, leukotriene modifiers, long-acting  $\beta_2$ -agonists (LABA), and biologic therapies 250 was positively associated with exacerbation count (S4 Table). Bivariate analyses comparing the 251 distribution of characteristics between the study cohort and patients excluded due to missing 252 EHR data found statistically significant differences in years followed, age, sex, health insurance 253 type, COPD, allergic rhinitis, Elixhauser comorbidity score, and ICS (p < 0.001) (S5 Table). 254 Based on Pearson's correlation coefficients, there were no strong correlations between 255 any EHR-derived or SEDH variables, except for NO<sub>2</sub> and PM2.5 ( $\rho = 0.77$ ) (S4 Fig). Moderate 256 correlations ( $|\rho| > 0.50$ ) were observed between age and Medicare health insurance, Black race 257 and ADI, and NO<sub>2</sub> and NDVI. Furthermore, adjusted generalized VIFs for all variables did not 258 exceed 2.00, suggesting that all variables could be included in multivariable models (S6 Table). 259 260 Individual risk factors associated with asthma exacerbations

261 ORs for the EHR-derived and SEDH variables included in the multivariable logistic regression

model are summarized in Table 2. The EHR-derived variables years followed, age 35-54, Black

263	race, and ICS had the strongest positive associations with having at least one exacerbation during
264	the study period ( $p < 0.001$ ) (Table 2). These effects persisted after additionally adjusting for
265	SEDH variables, and of the SEDH variables in the logistic regression model, only $NO_2$ exposure
266	was positively associated with exacerbations ( $p = 0.0058$ ). Inclusion of the SEDH variables did
267	not improve model fit as determined by AIC (8,323 versus 8,322). Sensitivity analyses showed
268	that the risk factors identified by logistic and negative binomial regression models were mostly
269	consistent, with Black race and ICS prescription having the strongest effects between both
270	models ( $p < 10^{-4}$ ), and variables such as Medicaid health insurance and Elixhauser comorbidity
271	score of 1-9 having statistically significant p-values in both models though smaller in the
272	negative binomial regression (p < 0.001) than the logistic regression (p < 0.05) (S7 Table).
273	However, the negative binomial regression model did not identify statistically significant
274	associations between asthma exacerbations and age 35-54 or NO <sub>2</sub> exposure as did the logistic
275	regression, although the directions of effect were consistent in both models. In addition, the
276	negative binomial regression model identified an association with the SEDH variable housing
277	code violations ( $p = 0.044$ ) that was not present in the logistic regression model.
278	

279 Spatial risk factors associated with exacerbations

Maps of ORs across the study region for the unadjusted, EHR-adjusted, and EHR & SEDHadjusted spatial GAMs are shown in Fig 2. In the unadjusted model, the global test of the null hypothesis that asthma exacerbations were not associated with geographic location was significant (p < 0.001) (Fig 2A). Local tests identified a statistically significant hotspot of exacerbations (p < 0.01) in West and South Philadelphia with a mean spatial OR of 1.42 (SD 0.14). In the model adjusted for EHR-derived variables (Fig 2B) the global test statistic remained

286	significant (p < 0.001). Local tests again identified a hotspot (p < 0.01) in West and South
287	Philadelphia which had a decreased mean spatial OR of 1.27 (SD 0.057). In this EHR-adjusted
288	model, the variance in spatial ORs across the study region was 33.8% lower than the variance of
289	the unadjusted model (S5 Fig). In the model adjusted for both EHR-derived and SEDH variables,
290	the global test statistic remained significant ( $p < 0.001$ , Fig 2C) and local tests identified a
291	hotspot (p < $0.01$ ) in West Philadelphia that overlapped geographically with the one in the other
292	models, although of a smaller area and with a smaller mean spatial OR of 1.24 (SD 0.040)
293	compared to the EHR-adjusted model. The variance in spatial ORs in the EHR & SEDH-
294	adjusted model was strongly attenuated (67.2% lower than that of the unadjusted model),
295	suggesting that these variables partially explained the spatial correlation of exacerbations (S5
296	Fig). The ORs for the other terms included in the spatial GAMs (i.e., the EHR-derived and
297	SEDH variables) are summarized in Table 3. All variables (i.e., years followed, age 35-54, Black
298	race, class 3 obesity, Medicaid health insurance, Elixhauser score 1-9, ICS) that were significant
299	in the multivariable logistic regression models (Table 2) were also significant in the spatial
300	GAMs (Table 3), except for NO <sub>2</sub> exposure, which was significant in the logistic regression
301	model but not in the spatial GAM.
302	In the spatial GAM models adjusted one variable at a time, ADI, race, and health
303	insurance type most strongly attenuated the variation in spatial ORs (Fig 3), individually

accounting for 55.2%, 38.5%, and 26.4%, respectively, of the variation in the unadjusted model

305 (S5 Fig). In these models, each variable was positively associated with exacerbations (p <

306 0.001): ADI with OR = 1.05 (95% CI: 1.03, 1.07); Black race with OR = 1.66 (95% CI: 1.44,

1.91); and Medicaid health insurance with OR = 1.30 (95% CI: 1.15, 1.46) (S8 Table). The

308 spatial distribution of these variables followed similar patterns: high ADI and high density of

Black patients and patients with Medicaid insurance cooccurred in West, North, and South
Philadelphia (Fig 3). No other EHR (S6 Fig) or SEDH (S7 Fig) variable attenuated the hotspot
area or its effect size, however, adjustment for NO<sub>2</sub> levels resulted in an expansion of a coldspot
area (S7A Fig).

313

#### 314 <u>Stratified analysis by race</u>

315 Bivariate analysis comparing the distribution of all EHR and SEDH characteristics between 316 patients of Black and White race found statistically significant differences for all variables 317 except ethnicity and ICS (Table 4). Given that ADI, race, and health insurance type had the 318 strongest relationship with asthma exacerbations in spatial analyses, and their spatial 319 distributions were similar, we performed stratified spatial analyses by race to determine whether 320 ADI and health insurance status remained significantly associated with asthma exacerbations 321 within race-stratified groups. After applying SRR inclusion criteria in strata according to race, an 322 additional 265 Black patients were excluded from the stratified spatial analysis, resulting in a 323 sample size of 4,363 patients (Fig 4A). The unadjusted spatial GAM for patients of Black race 324 had a significant global test statistic (p < 0.001) and local tests identified hotspots in West and 325 South Philadelphia consistent with results of the full cohort (Fig 4B). In contrast to spatial 326 analyses in the full cohort, adjusting for ADI and health insurance separately for Black patients 327 did not attenuate the spatial variance in ORs, instead increasing the variance by 4.70% and 328 2.68%, respectively, compared to the unadjusted model (Fig 4C and 4D). In patients of White 329 race, 73 additional patients were removed after applying SRR inclusion criteria, resulting in 330 1,383 patients included in the spatial model for which the global test statistic was no longer 331 significant (p = 0.079, S8 Fig).

332

#### 333 Discussion

334 Our analysis of individual-level risk factors found that Black race and ICS prescription had the 335 strongest positive associations with asthma exacerbations, as determined by individual-level 336 logistic regression and spatial GAM models. In our cohort of Penn Medicine asthma patients, 337 66% with no exacerbations were Black compared to 83% with 5+ exacerbations, consistent with 338 known racial disparities in asthma and observations in past Penn Medicine cohorts [44,45]. With 339 regard to the observed association between exacerbations and ICS prescription, international 340 asthma management guidelines underwent a major shift in 2019, recommending ICS as part of 341 the first-line treatment for all asthma patients [46]. This shift was not reflected in our cohort, 342 with only 76.0% of patients prescribed ICS. We observed exacerbations in patients in our cohort 343 regardless of whether they had an ICS prescription, however, the strong association between ICS 344 and exacerbations suggests that patients with more severe asthma were prescribed ICS more 345 frequently than those with milder asthma. Our sensitivity analysis found that logistic regression 346 identified positive associations between age 35-54 and NO<sub>2</sub> exposure that were not observed in a 347 negative binomial regression model, suggesting that these factors were associated with risk of 348 having at least one exacerbation compared to none, but not with having a higher count of 349 exacerbations.

Our spatial analysis of patient-level data revealed several important insights. First, we observed that asthma exacerbation risk across Philadelphia was spatially correlated and identified a hotspot with 42% higher odds of exacerbation compared to the median across the study region. This finding is consistent with the results of community-based pediatric asthma screening in Philadelphia, which have found that local asthma prevalence can vary significantly

355 from regional or national estimates [47]. Our findings are also consistent with studies that have 356 assessed spatial heterogeneity of pediatric and adult asthma data in other United States 357 metropolitan areas, albeit with less granular spatial resolution. Zárate et al. observed statistically 358 significant spatial patterning of asthma-related emergency department visits across census tracts 359 in Central Texas [48], Grunwell et al. identified a group of contiguous census tracts in the State 360 of Georgia with high rates of admission to the pediatric intensive care unit for asthma [49], and 361 Harris et al. and Corburn et al. identified a statistically significant cluster of zip codes in St. 362 Louis, Missouri and of census tracts in New York City, respectively, with elevated pediatric 363 asthma hospitalization rates [50,51]. Our observation of a West and South Philadelphia hotspot 364 of exacerbation risk is also consistent with analyses of past Penn Medicine cohorts [3,4] that 365 focused on validating methods for augmenting EHR datasets rather than identifying factors 366 associated with the hotspots.

The factors we found to be associated with asthma exacerbations according to EHR- and 367 368 EHR & SEDH- adjusted spatial GAM models were largely consistent with individual-level 369 logistic regression findings, but the spatial analysis provided an improved context to understand 370 the individual-level results. Adjusting for all EHR and SEDH variables decreased the variance in 371 spatial ORs by 67.2%, indicating that these variables together accounted for a large proportion of 372 the spatial variance in exacerbation odds. By adjusting the spatial model one variable at a time, 373 we found that ADI, race, and health insurance type most attenuated the hotspot area and effect 374 size by reducing the variance of spatial ORs, suggesting that these variables were the most 375 influential in determining the spatial distribution of exacerbation risk. Our findings are consistent 376 with known asthma disparities by race/ethnicity and socioeconomic status [7–11], as well as past 377 neighborhood-level analyses of pediatric asthma: Harris et al. and Corburn et al. found that

asthma hospitalization hotspots in St. Louis and New York City had greater proportions of nonWhite residents and greater rates of poverty, unemployment, high-density housing, and lack of
access to a household vehicle, although they did not test for statistical significance [50,51].
Grunwell et al. found a statistically significant difference between hotspot and non-hotspot
census tracts in Georgia for poverty, unemployment, and high-density housing, but not for race
[49].

384 Nearly all patient characteristics in our cohort, including health insurance type and ADI, 385 differed significantly between Black and White patients (Table 4). Most notably, 8.5% of White 386 patients had Medicaid health insurance compared to 38% of Black patients, and the median ADI 387 for White patients was 2.60 (IQR 1.50-4.30) compared to 8.40 for Black patients (IQR 6.50-388 9.40), making it difficult to assess confounding in our spatial models. Although the VIF 389 indicated that all variables could be included in a multivariable model without substantially 390 inflating variance, collinearity between race and ADI as well as race and health insurance type 391 (S4 Fig) may help explain why ADI and health insurance type were statistically significant in 392 bivariable spatial models but not in the EHR & SEDH-adjusted spatial GAM nor in the EHR & 393 SEDH-adjusted logistic regression (Tables 2 and 3). We attempted to overcome some of these 394 limitations by stratifying our analysis by race. We found that, unlike in the full cohort, adjusting 395 for ADI and health insurance type for Black patients did not attenuate the variance in spatial 396 ORs, suggesting that in our cohort the association between these variables and asthma 397 exacerbations was confounded by race. Our results are consistent with previous observations that 398 racial disparities in asthma control persist even after accounting socioeconomic status [52], but 399 that it is difficult to separate out the effects of socioeconomic status from the effects of race [53]. 400 Confounding of the asthma-socioeconomic status relationship by race has also been observed in

past neighborhood-level analyses of asthma morbidity. Zárate et al. found that spatial patterning
of asthma-related emergency department visits in Central Texas was partially explained by
socioeconomic characteristics in White patients, but not in Black or Hispanic patients [48]. More
broadly, understanding the relative contributions of many social determinants of health to asthma
is made difficult by their unequal distribution across racial/ethnic groups in the United States
[10].

407 Our health insurance type variable serves as a proxy for individual-level socioeconomic 408 status, and the relationship we measured between it and asthma exacerbation risk is potentially 409 mediated by several pathways including increased rates of smoking [54], psychosocial stress 410 [55], and obesity [56], or an unmeasured variable that varies with socioeconomic status and is also associated with minoritized racial and ethnicity groups in the United States [57]. On the 411 other hand, low neighborhood-level socioeconomic status, which we measured with ADI, is 412 413 associated with differential exposure to indoor and outdoor air pollution, psychosocial stress 414 from neighborhood violence, and community norms surrounding health behaviors, all of which 415 have been linked to asthma exacerbations [27]. Due to geographic segregation by race that 416 resulted from structural racism and is common in many US cities, including in Philadelphia as 417 we observed in our study, race and neighborhood-level SES are also highly correlated [58]. 418 Thus, our inability to identify an association between asthma exacerbations and ADI when 419 restricting our analysis to Black patients may be due to a restriction of the range of people across 420 the ADI spectrum relative to the range observed in all patients [48]. Future work is needed to 421 understand what specific SEDH variables that covary with race, ADI, and health insurance type 422 are the primary drivers of local disparities in asthma exacerbation risk across Philadelphia.

423 Our results demonstrate that integration of diverse SEDH datasets with the EHR and the 424 use of both spatial and non-spatial modeling approaches are helpful to understand factors 425 contributing to complex health conditions in real world populations. In both our logistic 426 regression models and spatial GAMs, model fit was not improved by adjusting for SEDH 427 variables in addition to EHR-derived variables. However, in our spatial models, adjusting for 428 SEDH variables resulted in twice as much reduction of the initial variance in spatial ORs 429 compared to adjusting for EHR variables only. Our non-spatial and spatial models also identified 430 different sets of factors associated with exacerbations. For example, ICS prescription was found 431 to have a strong positive association with exacerbations in logistic regression models but did not 432 contribute to the spatial distribution of ORs; conversely, ADI attenuated the variance in spatial ORs more strongly than all other variables tested but was not significant in either logistic 433 434 regression or negative binomial models. These findings present a framework for future efforts to 435 expand the scope of EHR data, which, especially as the spatial resolution of SEDH datasets continues to increase, will allow for improved individualized exposure estimates. In the future, 436 437 integration of SEDH data into the EHR may be helpful to tailor asthma management strategies 438 and for health systems to create population-level interventions to improve health of their patients. 439 This study is strengthened by the high spatial resolution of both our SEDH data and our 440 analysis. Integrating the highest resolution SEDH data available during the time of the study 441 period allowed us to most closely approximate individual-level exposures, and analyzing EHR 442 data at a fine resolution allowed us to understand local health patterns that may not be visible at 443 the census tract or zip-code level. Additional strengths included accounting for many variables 444 and increasing the likelihood that Penn Medicine was patients' primary care provider by 445 applying SRR restriction. Our study is also subject to limitations, including some related to use

of EHR data, such as missingness, entry error, and phenotype misclassification. Additionally, the
geocoded addresses used in our study reflect residence at the time of the data pull, but they do
not account for residential mobility during the study period, nor does residence information
provide a full assessment of environmental exposures.

450

#### 451 Conclusion

452 By integrating seven datasets containing information on SEDH with an EHR dataset to create

453 individualized exposure assessments, we identified non-spatial and spatial factors associated

454 with asthma exacerbations. Race and prescription of an ICS were most strongly associated with

455 exacerbations in individual-level models. Race also accounted for the most spatial variation in

456 exacerbation odds, along with ADI and health insurance type. Because these three variables had

457 similar spatial distributions, understanding which contributes most to disparities in asthma

458 exacerbations requires additional study of people living in the region identified as a hotspot. Our

459 findings demonstrate how integrating diverse data types and geospatial modeling approaches

460 with EHR data are helpful to understand complex diseases locally.

461

#### 462 Acknowledgements

We would like to thank Sunil Thomas from the University of Pennsylvania Penn Data Store forextracting the EHR data used for this project.

Table 1. Patient characteristics by exacerbation count levels. Shown are the characteristics of
patients according to their number of exacerbations during the study period. For each
exacerbation level, the number and percentage of patients are shown for categorical variables,

468 and the Median and Interquartile Range (IQR) are shown for continuous variables.

	Number of Exacerbations					
Changeteristic	0	1-2	3-4	5+	р-	
<b>Characteristic</b> <sup>a</sup>	N = 4,327	N = 1,810	N = 328	N = 191	value <sup>b</sup>	
Years followed	2.69 (1.89,	2.81 (1.96,	3.12 (2.48,	3.60 (2.82,	<10-4	
	3.32)	3.46)	3.64)	3.84)		
Age					<10-4	
18-34	1,498 (35%)	524 (29%)	82 (25%)	51 (27%)		
35-54	1,445 (33%)	688 (38%)	144 (44%)	81 (42%)		
55-74	1,198 (28%)	512 (28%)	87 (27%)	54 (28%)		
75+	186 (4.3%)	86 (4.8%)	15 (4.6%)	5 (2.6%)		
Sex					0.29	
Male	1,020 (24%)	397 (22%)	71 (22%)	51 (27%)		
Female	3,307 (76%)	1,413 (78%)	257 (78%)	140 (73%)		
Race					<10-4	
White	1,059 (24%)	325 (18%)	52 (16%)	20 (10%)		
Black	2,860 (66%)	1,349 (75%)	260 (79%)	159 (83%)		
Unknown/Other	408 (9.4%)	136 (7.5%)	16 (4.9%)	12 (6.3%)		
Ethnicity					0.10	
non-Hispanic/Latino	4,160 (96%)	1,747 (97%)	322 (98%)	188 (98%)		
Hispanic/Latino	167 (3.9%)	63 (3.5%)	6 (1.8%)	3 (1.6%)		
BMI					<10-4	
Not Overweight or Obese	908 (21%)	307 (17%)	48 (15%)	30 (16%)		
Overweight	1,008 (23%)	426 (24%)	81 (25%)	38 (20%)		
Class 1 Obesity	970 (22%)	381 (21%)	64 (20%)	40 (21%)		
Class 2 Obesity	651 (15%)	300 (17%)	40 (12%)	40 (21%)		
Class 3 Obesity	790 (18%)	396 (22%)	95 (29%)	43 (23%)		
Health insurance type					<10-4	
Private	1,978 (46%)	736 (41%)	131 (40%)	49 (26%)		
Medicaid	1,270 (29%)	624 (34%)	113 (34%)	87 (46%)		
Medicare	1,079 (25%)	450 (25%)	84 (26%)	55 (29%)		
Smoking status	1,073 (2070)				<10-4	
Never Smoked	2,533 (59%)	997 (55%)	167 (51%)	84 (44%)		
Ever Smoker	1,233 (28%)	517 (29%)	110 (34%)	77 (40%)		
Current Smoker	561 (13%)	296 (16%)	51 (16%)	30 (16%)		
COPD	398 (9.2%)	219 (12%)	44 (13%)	30 (16%)	<10-4	
Allergic rhinitis	1,478 (34%)	636 (35%)	133 (41%)	104 (54%)	<10-4	
Elixhauser comorbidity score	1,1,0 (01,0)		100 (11/0)		<10-4	
<0	220 (5.1%)	85 (4.7%)	21 (6.4%)	5 (2.6%)	10	
0	3,035 (70%)	1,214 (67%)	193 (59%)	99 (52%)		
1-9	723 (17%)	356 (20%)	71 (22%)	60 (31%)		
10+	349 (8.1%)	155 (8.6%)	43 (13%)	27 (14%)		
ICS	3,074 (71%)	1,489 (82%)	309 (94%)	188 (98%)	<10-4	
NO <sub>2</sub> exposure	7.20 (6.86,	7.18 (6.90,	7.24 (6.86,	7.14 (6.78,	0.35	
1102 caposure	7.20 (0.80,	7.70)	7.79)	7.56)	0.55	
PM2.5 exposure	8.20 (7.84,	8.16 (7.81,	8.22 (7.86,	8.14 (7.78,	0.018	
I III III CAPOSULC	8.65)	8.62)	8.62)	8.58)	0.010	
Toxic releases exposure	231 (5.3%)	87 (4.8%)	18 (5.5%)	10 (5.2%)	0.85	
Vehicular traffic exposure	231 (3.370)	07 (1.070)	10 (0.070)	10 (0.270)	0.095	

Lowest	1,079 (25%)	447 (25%)	85 (26%)	53 (28%)	
Low	1,079 (25%)	441 (24%)	96 (29%)	48 (25%)	
High	1,046 (24%)	485 (27%)	80 (24%)	53 (28%)	
Highest	1,123 (26%)	437 (24%)	67 (20%)	37 (19%)	
Area deprivation index	7.00 (3.50,	7.80 (4.30,	7.70 (5.30,	7.80 (5.25,	<10-4
	9.10)	9.20)	9.13)	9.30)	
Housing violations	0.80 (0.36,	0.83 (0.39,	0.90 (0.45,	0.84 (0.38,	0.083
	1.47)	1.49)	1.61)	1.28)	
Normalized difference vegetation	0.21 (0.17,	0.21 (0.17,	0.21 (0.16,	0.22 (0.19,	0.26
index	0.27)	0.26)	0.27)	0.26)	

470 <sup>a</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

471  $(\mu g/m^3)$ , toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by

472 dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

473 (unitless index ranging from -1 to 1). See Methods for more details.

474 <sup>b</sup>Kruskal-Wallis rank sum test; Pearson's Chi-squared test

#### 475 Table 2. Individual-level asthma exacerbation risk factors in multivariable logistic

regression models. Shown are the adjusted odds ratios (ORs), 95% confidence intervals (CIs),
and p-values for logistic regression models of asthma exacerbations as a dichotomous outcome
adjusted for EHR-derived variables only and for both EHR and SEDH variables.

		EHR-adjust	ted	EHF	R & SEDH-a	djusted
Characteristic <sup>a</sup>	OR	95% ČI	p-value	OR	95% CI	p-value
Years followed	1.16	1.09, 1.24	<10-4	1.17	1.09, 1.24	<10-4
Age		,			,	
18-34					<u> </u>	
35-54	1.26	1.11, 1.44	5.7x10 <sup>-4</sup>	1.27	1.11, 1.45	4.0x10 <sup>-4</sup>
55-74	1.08	0.91, 1.27	0.38	1.09	0.92, 1.28	0.33
75+	1.29	0.96, 1.73	0.095	1.33	0.98, 1.79	0.064
Sex		0.50, 1.70	0.070	1.00	0.50, 1.75	0.001
Male						
Female	0.98	0.87, 1.12	0.79	0.98	0.86, 1.11	0.77
Race	0.50	0.07, 1.12	0.15	0.90	0.00, 1.11	0.77
White					<u> </u>	
Black	1.48	1.29, 1.72	<10-4	1.52	1.28, 1.81	<10-4
Unknown/Other	1.40	0.79, 1.28	0.95	1.01	0.79, 1.29	0.94
Ethnicity	1.01	0.79, 1.20	0.75	1.01	0.17, 1.29	0.77
Non-Hispanic/Latino					<u>  _</u>	
Hispanic/Latino	0.99	0.71, 1.36	0.94	0.98	0.71, 1.35	0.91
BMI	0.99	0.71, 1.30	0.94	0.98	0.71, 1.55	0.91
Not Overweight or Obese						
Overweight	1.15	0.98, 1.36	0.088	1.16	0.98, 1.37	0.079
Class 1 Obesity	0.99	0.38, 1.30	0.088	1.10	0.98, 1.37	0.079
Class 2 Obesity	1.09	0.83, 1.17	0.87	1.00	0.84, 1.18	0.35
Class 3 Obesity	1.09	1.04, 1.48	0.36	1.09	1.04, 1.49	0.33
Health insurance type	1.24	1.04, 1.48	0.017	1.23	1.04, 1.49	0.015
Private						
Medicaid	1.22		0.0026	1.19	1.04.1.26	0.012
		1.07, 1.39	0.0036		1.04, 1.36	0.013
Medicare	0.91	0.77, 1.06	0.23	0.89	0.76, 1.05	0.17
Smoking status						
Never Smoked	1.04		0.52			0.56
Ever Smoker	1.04	0.92, 1.18	0.52	1.04	0.92, 1.18	0.56
Current Smoker	1.17	1.0, 1.37	0.057	1.16	0.98, 1.36	0.075
COPD						
No			0.15			0.04
Yes	1.14	0.95, 1.36	0.17	1.11	0.93, 1.34	0.24
Allergic rhinitis						
No				—	<u> </u>	
Yes	1.09	0.97, 1.22	0.13	1.09	0.98, 1.22	0.11
Elixhauser comorbidity score						
<0		<u> </u>			<u> </u>	
0	1.20	0.94, 1.54	0.14	1.20	0.94, 1.54	0.14
1-9	1.40	1.08, 1.83	0.012	1.39	1.07, 1.82	0.015
10+	1.20	0.89, 1.62	0.22	1.19	0.89, 1.61	0.25
ICS						
No					<u> </u>	
Yes	2.19	1.91, 2.51	<10-4	2.20	1.92, 2.52	<10-4
NO <sub>2</sub> exposure				1.28	1.07, 1.52	0.0058
PM2.5 exposure				0.89	0.72, 1.09	0.25

Toxic releases exposure					
No					
Yes			1.07	0.83, 1.37	0.60
Vehicular traffic exposure					
Lowest					
Low			1.01	0.88, 1.17	0.86
High			1.10	0.95, 1.28	0.18
Highest			0.95	0.82, 1.11	0.54
Area deprivation index			1.02	0.99, 1.04	0.22
Housing violations			0.96	0.90, 1.01	0.11
Normalized difference vegetation			1.08	0.47, 2.44	0.86
index					
AIC	8,323		8,322		

480 <sup>a</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

481  $(\mu g/m^3)$ , toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by

482 dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

483 (unitless index ranging from -1 to 1). See Methods for more details.

#### 484 **Table 3. Spatial asthma exacerbation risk factors in multivariable spatial GAMs.** Shown are

the adjusted odds ratios (ORs), 95% confidence intervals (CIs), and p-values for spatial GAMs of
asthma exacerbations as a dichotomous outcome adjusted for EHR-derived variables only and
for both EHR-derived and SEDH variables.

		EHR-adjust		EHF	R & SEDH-a	djusted
<b>Characteristic</b> <sup>a</sup>	OR	95% CI	p-value	OR	95% CI	p-value
Years followed	1.17	1.10, 1.25	<10-4	1.17	1.09, 1.25	<10-4
Age						
18-34						
35-54	1.27	1.11, 1.45	3.7x10 <sup>-4</sup>	1.27	1.11, 1.45	3.9x10 <sup>-4</sup>
55-74	1.07	0.91, 1.26	0.42	1.07	0.91, 1.27	0.41
75+	1.30	0.97, 1.75	0.083	1.31	0.97, 1.77	0.075
Sex		,			,	
Male						
Female	0.99	0.87, 1.12	0.82	0.98	0.87, 1.12	0.81
Race		,			,	
White						
Black	1.58	1.35, 1.84	<10-4	1.55	1.30, 1.84	<10-4
Unknown/Other	1.03	0.81, 1.31	0.82	1.01	0.79, 1.30	0.91
Ethnicity		,	-	-	,	
non-Hispanic/Latino						
Hispanic/Latino	1.03	0.74, 1.42	0.88	1.02	0.73, 1.41	0.92
BMI						
Not Overweight or Obese						
Overweight	1.17	0.99, 1.37	0.065	1.16	0.99, 1.37	0.070
Class 1 Obesity	1.00	0.84, 1.18	0.99	1.00	0.84, 1.18	0.98
Class 2 Obesity	1.10	0.91, 1.32	0.34	1.09	0.91, 1.32	0.36
Class 3 Obesity	1.25	1.05, 1.50	0.012	1.25	1.05, 1.49	0.013
Health insurance type		1.00, 1.00	0.012	1.20	1.00, 1.13	0.012
Private						
Medicaid	1.18	1.03, 1.34	0.015	1.18	1.03, 1.34	0.019
Medicare	0.90	0.76, 1.05	0.17	0.89	0.76, 1.05	0.17
Smoking status	0.70	0.70, 1.00	0.17	0.05	0.70, 1.00	0.17
Never Smoked						
Ever Smoker	1.04	0.91, 1.17	0.58	1.03	0.91, 1.17	0.60
Current Smoker	1.15	0.98, 1.35	0.092	1.15	0.98, 1.35	0.093
COPD	1.1.5	0.70, 1.55	0.072	1.1.0	0.70, 1.55	0.075
No						
Yes	1.10	0.92, 1.32	0.30	1.10	0.92, 1.32	0.29
Allergic rhinitis	1.10	0.72, 1.32	0.50	1.10	0.72, 1.32	0.27
No						
Yes	1.09	0.98, 1.22	0.12	1.10	0.98, 1.22	0.11
Elixhauser comorbidity score	1.07	0.76, 1.22	0.12	1.10	0.96, 1.22	0.11
<0						
	1.20	0.94, 1.54	0.14	1.20	0.94, 1.53	0.15
1-9	1.39	1.06, 1.81	0.014	1.20	1.06, 1.80	0.018
1-9 10+	1.19	0.87, 1.59	0.010	1.38	0.87, 1.58	0.018
	1.10	0.07, 1.39	0.20	1.1/	0.07, 1.30	0.27
No						
Yes	2.22	1.93, 2.54	<10-4	2.21	1.93, 2.54	<10-4
	2.22	1.93, 2.34	~10 .		<i>,</i>	0.56
NO <sub>2</sub> exposure				1.09	0.82, 1.44	
PM2.5 exposure				1.08	0.81, 1.45	0.59

Toxic releases exposure					
No					
Yes			1.06	0.82, 1.37	0.65
Vehicular traffic exposure					
Lowest				_	
Low			1.02	0.88, 1.19	0.76
High			1.10	0.95, 1.27	0.21
Highest			0.97	0.83, 1.13	0.66
Area deprivation index			1.01	0.99, 1.04	0.32
Housing violations			0.97	0.91, 1.02	0.23
Normalized difference vegetation					
index			0.99	0.43, 2.27	0.97
$\operatorname{AIC}^{b}$	8,296		8,309		

489 <sup>a</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

490  $(\mu g/m^3)$ , toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by

491 dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

492 (unitless index ranging from -1 to 1). See Methods for more details.

493 b The AIC of the unadjusted model was 8,576.

494 **Table 4. Patient characteristics by race.** Shown are the number and percentage of patients in

495 each level for categorical variables, and the Median and Interquartile Range (IQR) for

496 continuous variables in patients of White race versus Black race.

<sup>497</sup> 

	Ra		
Characteristica	White	Black	
<b>Characteristic</b> <sup>a</sup>	N = 1,456	N = 4,628	<b>p-value</b> <sup>b</sup>
Exacerbation count			<10-4
0	1,059 (73%)	2,860 (62%)	
1-2	325 (22%)	1,349 (29%)	
3-4	52 (3.6%)	260 (5.6%)	
5+	20 (1.4%)	159 (3.4%)	
Years followed	2.62 (1.86, 3.28)	2.82 (1.98, 3.46)	<10-4
Age			<10-4
18-34	468 (32%)	1,458 (32%)	
35-54	481 (33%)	1,667 (36%)	
55-74	407 (28%)	1,332 (29%)	
75+	100 (6.9%)	171 (3.7%)	
Sex			<10-4
Male	473 (32%)	905 (20%)	
Female	983 (68%)	3,723 (80%)	
Ethnicity			0.0024
non-Hispanic/Latino	1,431 (98%)	4,591 (99%)	
Hispanic/Latino	25 (1.7%)	37 (0.8%)	
BMI			<10-4
Not Overweight or Obese	521 (36%)	636 (14%)	
Overweight	462 (32%)	935 (20%)	
Class 1 Obesity	264 (18%)	1,048 (23%)	
Class 2 Obesity	106 (7.3%)	862 (19%)	
Class 3 Obesity	103 (7.1%)	1,147 (25%)	
Health insurance type			<10-4
Private	981 (67%)	1,624 (35%)	
Medicaid	124 (8.5%)	1,781 (38%)	
Medicare	351 (24%)	1,223 (26%)	
Smoking status		-, (,,,)	<10-4
Never Smoked	898 (62%)	2,519 (54%)	
Ever Smoker	463 (32%)	1,328 (29%)	
Current Smoker	95 (6.5%)	781 (17%)	
COPD	115 (7.9%)	536 (12%)	<10-4
Allergic rhinitis	571 (39%)	1,541 (33%)	<10-4
Elixhauser comorbidity score		1,011(0070)	<10-4
<0	32 (2.2%)	262 (5.7%)	10
0	1,117 (77%)	2,986 (65%)	
1-9	222 (15%)	924 (20%)	
10+	85 (5.8%)	456 (9.9%)	
ICS	1,105 (76%)	3,510 (76%)	0.97
NO <sub>2</sub> exposure	7.85 (7.40, 8.18)	7.10 (6.81, 7.39)	<10-4
PM2.5 exposure	8.72 (8.28, 8.90)	8.05 (7.77, 8.41)	<10-4
Toxic releases exposure	115 (7.9%)	194 (4.2%)	<10-4
Vehicular traffic exposure		1.2.0)	<10-4
Lowest	279 (19%)	1,283 (28%)	10
Low	267 (18%)	1,244 (27%)	
High	312 (21%)	1,177 (25%)	
111511	512 (21/0)	1,177 (2370)	1

Highest	598 (41%)	924 (20%)	
Area deprivation index	2.60 (1.50, 4.30)	8.40 (6.50, 9.40)	<10-4
Housing violations	0.41 (0.15, 0.74)	0.99 (0.52, 1.68)	<10-4
Normalized difference vegetation index	0.18 (0.13, 0.25)	0.22 (0.18, 0.27)	<10-4

498 <sup>a</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

499 (µg/m<sup>3</sup>), toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by

500 dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

501 (unitless index ranging from -1 to 1). See Methods for more details.

502 <sup>b</sup>Pearson's Chi-squared test; Wilcoxon rank sum test

#### 503 Figure Legends

504 Figure 1. Overview of study design. Graphical overview of study design, including processing 505 and linkage of electronic health record (EHR) and social and environmental determinants of 506 health (SEDH) data, cohort selection including spatial filtering by assessing the representation of 507 the EHR cohort compared to the underlying population, and patient-level and geospatial analyses 508 on the expanded EHR dataset. 509 Figure 2. Spatial odds ratios (ORs) of exacerbations before and after adjusting for EHRderived and SEDH variables. (A) Unadjusted spatial GAM (adjusted only for years followed). 510 511 (B) Spatial GAM adjusted for EHR-derived variables only. (C) Spatial GAM adjusted for both 512 EHR-derived and SEDH variables. Base maps were created using the Stamen Design from 513 Stadia Maps. 514 Figure 3. Spatial distribution of individual variables that most strongly attenuated the 515 spatial odds ratios (ORs) of exacerbations along with corresponding spatial GAM results 516 adjusted for these individual variables. Spatial distribution in the study region of (A) the area 517 deprivation index (ADI), (B) race, and (C) health insurance type of patients. Corresponding 518 spatial GAMs adjusted only for years followed and (D) ADI, (E) race, or (F) health insurance 519 type. 520 Figure 4. Spatial odds ratios (ORs) of exacerbations among Black patients along with the 521 effects of ADI and health insurance type on this distribution. (A) SRR values for the updated 522 study region used in spatial GAMs for patients of Black race only (SRR = 1 indicates no 523 representativeness bias). (B) Unadjusted spatial GAM (adjusted only for years followed) for

524 patients of Black race (N = 4,363). Spatial GAMs adjusted additionally for (C) area deprivation

- 525 index (ADI) and (D) health insurance type. Base maps were created using the Stamen Design
- 526 from Stadia Maps.

### 527 References

- Mooney SJ, Westreich DJ, El-Sayed AM. Commentary: Epidemiology in the era of big data.
   Epidemiology. 2015;c: 390–394. doi:10.1097/EDE.00000000000274
- Cook LA, Sachs J, Weiskopf NG. The quality of social determinants data in the electronic health record: a systematic review. J Am Med Inform Assoc JAMIA. 2021;29: 187–196. doi:10.1093/jamia/ocab199
- Xie S, Greenblatt R, Levy MZ, Himes BE. Enhancing Electronic Health Record Data with
   Geospatial Information. AMIA Summits Transl Sci Proc. 2017;2017: 123–132.
- 536 4. Xie S, Himes BE. Approaches to link geospatially varying social, economic, and
  537 environmental factors with electronic health record data to better understand asthma
  538 exacerbations. AMIA Annu Symp Proc. 2018;2018: 1561–1570.
- 5. Cui Y, Eccles KM, Kwok RK, Joubert BR, Messier KP, Balshaw DM. Integrating multiscale
  geospatial environmental data into large population health studies: challenges and
  opportunities. Toxics. 2022;10: 403. doi:10.3390/toxics10070403
- 542 6. Schreibman A, Xie S, Hubbard RA, Himes BE. Linking ambient NO2 pollution measures
  543 with electronic health record data to study asthma exacerbations. AMIA Summits Transl
  544 Sci Proc. 2023;2023: 467–476.
- 545 7. CDC. Asthma: most recent national asthma data. Atlanta, GA: US Department of Health and
  546 Human Services, CDC; 2020. Available:
  547 https://www.cdc.gov/asthma/most recent national asthma data.htm
- Leong AB, Ramsey CD, Celedón JC. The challenge of asthma in minority populations. Clin Rev Allergy Immunol. 2012;43: 156–183. doi:10.1007/s12016-011-8263-1
- 550 9. Forno E, Celedón JC. Health disparities in asthma. Am J Respir Crit Care Med. 2012;185:
  551 1033–1035. doi:10.1164/rccm.201202-0350ED
- 552 10. Grant T, Croce E, Matsui EC. Asthma and the social determinants of health. Ann Allergy
  553 Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2022;128: 5–11.
  554 doi:10.1016/j.anai.2021.10.002
- Lovinsky-Desir S, Riley IL, Bryant-Stephens T, De Keyser H, Forno E, Kozik AJ, et al.
  Research priorities in pediatric asthma morbidity: addressing the impacts of systemic
  racism on children with asthma in the United States: an official American Thoracic Society
  workshop report. Ann Am Thorac Soc. 2024;21: 1349–1364.
- 559 doi:10.1513/AnnalsATS.202407-767ST
- 560 12. Global Initiative for Asthma (GINA). Global strategy for asthma management and
   561 prevention (2024 update). Bethesda, MD: Global Initiative for Asthma (GINA); 2024.

- 562 13. Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA, Gern J, et al. Asthma
  563 outcomes: exacerbations. J Allergy Clin Immunol. 2012;129: S34–S48.
  564 doi:10.1016/j.jaci.2011.12.983
- Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, et al. Mortality
  in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit
  Care Med. 2006;174: 633–638. doi:10.1164/rccm.200601-007OC
- 15. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of
  asthma exacerbations on health care costs among asthmatic patients with moderate and
  severe persistent asthma. J Allergy Clin Immunol. 2012;129: 1229–1235.
  doi:10.1016/j.jaci.2012.01.039
- 572 16. Schatz M, Clark S, Camargo CA. Sex differences in the presentation and course of asthma
  573 hospitalizations. Chest. 2006;129: 50–55. doi:10.1378/chest.129.1.50
- 574 17. Schatz M, Mosen DM, Kosinski M, Vollmer WM, Magid DJ, O'Connor E, et al. Predictors
  575 of asthma control in a random sample of asthmatic patients. J Asthma. 2007;44: 341–345.
  576 doi:10.1080/02770900701344421
- 18. Pedersen SE, Bateman ED, Bousquet J, Busse WW, Yoxall S, Clark TJ. Determinants of
  response to fluticasone propionate and salmeterol/fluticasone propionate combination in the
  Gaining Optimal Asthma controL study. J Allergy Clin Immunol. 2007;120: 1036–1042.
  doi:10.1016/j.jaci.2007.07.016
- 19. Price D, Zhang Q, Kocevar VS, Yin DD, Thomas M. Effect of a concomitant diagnosis of
  allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy. 2005;35:
  282–287. doi:10.1111/j.1365-2222.2005.02182.x
- 584 20. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: A key predictor of
   585 future exacerbations. Respir Med. 2007;101: 481–489. doi:10.1016/j.rmed.2006.07.005
- 586 21. Guarnieri M, Balmes JR. Outdoor air pollution and asthma. The Lancet. 2014;383: 1581–
   587 1592. doi:10.1016/S0140-6736(14)60617-6
- Weitzman M, Gortmaker S, Sobol A. Racial, social, and environmental risks for childhood asthma. Am J Dis Child. 1990;144: 1189–1194.
  doi:10.1001/archpedi.1990.02150350021016
- 591 23. Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life 592 threatening asthma. Allergy. 2000;55: 501–504. doi:10.1034/j.1398-9995.2000.00293.x
- 593 24. Gelber LE, Seltzer LH, Bouzoukis JK, Pollart SM, Chapman MD, Platts-Mills TAE.
  594 Sensitization and exposure to indoor allergens as risk factors for asthma among patients
  595 presenting to hospital. Am Rev Respir Dis. 1993;147: 573–578.
  596 doi:10.1164/ajrccm/147.3.573

597 25. Lovasi GS, O'Neil-Dunne JPM, Lu JWT, Sheehan D, Perzanowski MS, MacFaden SW, et
598 al. Urban tree canopy and asthma, wheeze, rhinitis, and allergic sensitization to tree pollen
599 in a New York City birth cohort. Environ Health Perspect. 2013;121: 494–500.
600 doi:10.1289/ehp.1205513

- 601 26. Lovasi GS, Quinn JW, Neckerman KM, Perzanowski MS, Rundle A. Children living in areas
  602 with more street trees have lower prevalence of asthma. J Epidemiol Community Health.
  603 2008;62: 647–649. doi:10.1136/jech.2007.071894
- 604 27. Gold DR, Wright R. Population disparities in asthma. Annu Rev Public Health. 2005;26: 89–
  605 113. doi:10.1146/annurev.publhealth.26.021304.144528
- Fecho K, Ahalt SC, Appold S, Arunachalam S, Pfaff E, Stillwell L, et al. Development and
  application of an open tool for sharing and analyzing integrated clinical and environmental
  exposures data: asthma use case. JMIR Form Res. 2022;6: e32357. doi:10.2196/32357
- Beck AF, Huang B, Ryan PH, Sandel MT, Chen C, Kahn RS. Areas with high rates of
  police-reported violent crime have higher rates of childhood asthma morbidity. J Pediatr.
  2016;173: 175-182.e1. doi:10.1016/j.jpeds.2016.02.018
- 30. Rasmussen SG, Ogburn EL, McCormack M, Casey JA, Bandeen-Roche K, Mercer DG, et al.
  Association between unconventional natural gas development in the Marcellus Shale and
  asthma exacerbations. JAMA Intern Med. 2016;176: 1334–1343.
  doi:10.1001/jamainternmed.2016.2436
- 31. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the
  Elixhauser comorbidity measures into a point system for hospital death using administrative
  data. Med Care. 2009;47: 626. doi:10.1097/MLR.0b013e31819432e5
- 619 32. Christie C, Xie S, Diwadkar AR, Greenblatt RE, Rizaldi A, Himes BE. Consolidated
  620 Environmental and Social Data Facilitates Neighborhood-Level Health Studies in
  621 Philadelphia. AMIA Annu Symp Proc. 2022;2021: 305–313.
- 33. Cooper MJ, Martin RV, McLinden CA, Brook JR. Inferring ground-level nitrogen dioxide
  concentrations at fine spatial resolution applied to the TROPOMI satellite instrument.
  Environ Res Lett. 2020;15: 104013. doi:10.1088/1748-9326/aba3a5
- 34. van Donkelaar A, Hammer MS, Bindle L, Brauer M, Brook JR, Garay MJ, et al. Monthly
  global estimates of fine particulate matter and their uncertainty. Environ Sci Technol.
  2021;55: 15287–15300. doi:10.1021/acs.est.1c05309
- 35. US EPA. TRI basic data files: calendar years 1987-present. 3 Mar 2013 [cited 25 Jul 2023].
   Available: https://www.epa.gov/toxics-release-inventory-tri-program/tri-basic-data-files calendar-years-1987-present
- 631 36. RMSTRAFFIC (Traffic Volumes). 2023 [cited 25 Jul 2023]. Available: https://data 632 pennshare.opendata.arcgis.com/datasets/rmstraffic-traffic-volumes/explore

- 633 37. Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible the
  634 neighborhood atlas. N Engl J Med. 2018;378: 2456–2458. doi:10.1056/NEJMp1802313
- 38. University of Wisconsin School of Medicine Public Health. 2018 Area Deprivation Index
   v3.1. Available: https://www.neighborhoodatlas.medicine.wisc.edu/. Accessed July 2022.
- 637 39. Licenses and Inspections code violations. In: OpenDataPhilly [Internet]. [cited 25 Jul 2023].
   638 Available: https://opendataphilly.org/datasets/licenses-and-inspections-code-violations/
- 639 40. Ermida SL, Soares P, Mantas V, Göttsche F-M, Trigo IF. Google Earth Engine open-source
  640 code for land surface temperature estimation from the Landsat series. Remote Sens.
  641 2020;12: 1471. doi:10.3390/rs12091471
- 642 41. R Core Team (2020). R: a language and environment for statistical computing. Vienna,
   643 Austria: R Foundation for Statistical Computing; Available: https://www.R-project.org/
- 42. Xie SJ, Kapos FP, Mooney SJ, Mooney S, Stephens KA, Chen C, et al. Geospatial divide in
  real-world EHR data: analytical workflow to assess regional biases and potential impact on
  health equity. AMIA Summits Transl Sci Proc. 2023;2023: 572–581.
- 647 43. Bai L, Bartell S, Bliss R, Vieira V. Mapping smoothed effect estimates from individual-level
  648 spatial data. 2022. Available: https://search.r649 project.org/CRAN/refmans/MapGAM/html/MapGAM-package.html
- 44. Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, et al. National
  surveillance of asthma: United States, 2001-2010. Vital Health Stat 3. 2012; 1–58.
- 45. Greenblatt RE, Zhao EJ, Henrickson SE, Apter AJ, Hubbard RA, Himes BE. Factors
  associated with exacerbations among adults with asthma according to electronic health
  record data. Asthma Res Pract. 2019;5: 1. doi:10.1186/s40733-019-0048-y
- 46. Global Initiative for Asthma (GINA). Global strategy for asthma management and
  prevention (2019 update). Bethesda, MD: Global Initiative for Asthma (GINA); 2019.
- 47. Bryant-Stephens T, West C, Dirl C, Banks T, Briggs V, Rosenthal M. Asthma prevalence in philadelphia: description of two community-based methodologies to assess asthma
  prevalence in an inner-city population. J Asthma. 2012;49: 581–585.
  doi:10.3109/02770903.2012.690476
- 48. Zárate RebeccaA, Bhavnani D, Chambliss S, Hall EM, Zigler C, Cubbin C, et al.
  Neighborhood-level variability in asthma-related emergency department visits in Central Texas. J Allergy Clin Immunol. 2024;154: 933–939. doi:10.1016/j.jaci.2024.05.024
- 664 49. Grunwell JR, Opolka C, Mason C, Fitzpatrick AM. Geospatial analysis of social
  665 determinants of health identifies neighborhood hot spots associated with pediatric intensive
  666 care use for life-threatening asthma. J Allergy Clin Immunol Pract. 2022;10: 981-991.e1.
  667 doi:10.1016/j.jaip.2021.10.065

- 50. Harris KM. Mapping inequality: Childhood asthma and environmental injustice, a case study
   of St. Louis, Missouri. Soc Sci Med. 2019;230: 91–110.
- 670 doi:10.1016/j.socscimed.2019.03.040
- 51. Corburn J, Osleeb J, Porter M. Urban asthma and the neighbourhood environment in New
  York City. Health Place. 2006;12: 167–179. doi:10.1016/j.healthplace.2004.11.002
- 52. Haselkorn T, Lee JH, Mink DR, Weiss ST. Racial disparities in asthma-related health
  outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2008;101:
  256–263. doi:10.1016/S1081-1206(10)60490-5
- 53. Boudreaux ED, Emond SD, Clark S, Camargo CA. Acute asthma among adults presenting to
  the emergency department: the role of race/ethnicity and socioeconomic status. Chest.
  2003;124: 803–812. doi:10.1378/chest.124.3.803
- 54. Hiscock R, Bauld L, Amos A, Fidler JA, Munafò M. Socioeconomic status and smoking: a review. Ann N Y Acad Sci. 2012;1248: 107–123. doi:10.1111/j.1749-6632.2011.06202.x
- 55. Matthews KA, Gallo LC, Taylor SE. Are psychosocial factors mediators of socioeconomic
  status and health connections? Ann N Y Acad Sci. 2010;1186: 146–173.
  doi:10.1111/j.1749-6632.2009.05332.x
- 56. Wang Y, Beydoun MA. The obesity epidemic in the United States—gender, age,
  socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and metaregression analysis. Epidemiol Rev. 2007;29: 6–28. doi:10.1093/epirev/mxm007
- 57. Williams DR. Race, socioeconomic status, and health: the added effects of racism and
  discrimination. Ann N Y Acad Sci. 1999;896: 173–188. doi:10.1111/j.17496632.1999.tb08114.x
- 58. Charles CZ. The dynamics of racial residential segregation. Annu Rev Sociol. 2003;29: 167–207. doi:10.1146/annurev.soc.29.010202.100002

#### 693 Supporting information

#### 694 S1 Text. Supplementary Methods.

- 695 S1 Figure. Flowchart of patient cohort selection. Overview of steps followed to select final
- patient cohort (N = 6,656) from EHR data on all Penn Medicine patients with at least one asthma
- 697 ICD code (N = 86,787).

#### 698 S2 Figure. Selection of study region using the spatial representation ratio (SRR). (A) SRR

values, defined as the cohort population residing in a block group divided by the underlying

population as reported by the 2019 American Community Survey, for all of Philadelphia and for

the selected study region (inset box). SRR = 1 indicates no representativeness bias. Density plots

of the study cohort (B) before and (C) after filtering for the study region. Base maps were created

vising the Stamen Design from Stadia Maps.

#### **S3** Figure. Spatial distribution of SEDH datasets that were integrated with EHR data.

The following maps are shown for the spatial area which comprised our study region: (A) raster

of NO2 pollution levels, (B) raster of PM2.5 pollution levels, (C) point sites of toxic releases and

the total summed emissions at each site, (D) line segments of roadways and the daily vehicle

708 miles traveled (DVDT) on each, (E) housing violations per block group, normalized by the

- underlying 2019 American Community Survey population, (F) raster of the normalized
- 710 difference vegetation index (NDVI). A map of area deprivation index (ADI), which most
- strongly reduced the spatial variance of odds of exacerbation risk in our spatial GAMs, is shown
- in Figure 3A. Base maps were created using the Stamen Design from Stadia Maps.

#### 713 S4 Figure. Pairwise correlation between all EHR and SEDH variables. Measures in each box

714 correspond to Pearson's correlation coefficients. For nominal categorical variables, reference

715 levels are as follows: White (race), Private (health insurance type).

#### 716 S5 Figure. Influence of individual EHR and SEDH variables on the odds ratio (OR) of the

717 unadjusted spatial GAM. Percent reduction in the variance of ORs across the study region for

one-variable-at-a-time adjusted spatial GAMs compared to the unadjusted model. OR changes

for models adjusted one variable at a time (in addition to years followed) are shown in blue.

- 720 Multivariable models (both EHR-adjusted and EHR & SEDH-adjusted) are shown in red for
- 721 comparison.

#### 722 S6 Figure. Spatial GAMs adjusted one-at-a-time for the EHR-derived variables that did

723 not greatly reduce variance. Spatial odds ratios (ORs) of exacerbation are shown after

- adjusting for years followed and one-at-a-time for the following variables whose percent
- reduction in variance of ORs was less than 25: (A) age, (B) sex, (C) ethnicity, (D) BMI, (E)

smoking status, (F) COPD, (G) allergic rhinitis, (H) Elixhauser comorbidity score, (I) ICS. Base

727 maps were created using the Stamen Design from Stadia Maps.

#### 728 S7 Figure. Spatial GAMs adjusted one-at-a-time for the SEDH variables that did not

729 greatly reduce variance. Spatial odds ratios (ORs) of exacerbation are shown after adjusting for

years followed and one-at-a-time for the following variables whose reduction in variance of ORs

731 was less than 25: (A) NO2, (B) PM2.5, (C) toxic releases exposure, (D) vehicular traffic, (E)

housing violations, (F) normalized difference vegetation index (NDVI). Base maps were created

vising the Stamen Design from Stadia Maps.

#### 734 S8 Figure. Spatial odds ratios (ORs) of exacerbations among White patients along with the

race reflects of ADI and health insurance type on this distribution. (A) SRR values for the updated

- study region used in spatial GAMs for patients of White race only (SRR = 1 indicates no
- 737 representativeness bias). (B) Unadjusted spatial GAM adjusted only for years followed for
- patients of White race (N = 1,383). Spatial GAMs adjusted additionally for (C) area deprivation

index (ADI) and (D) health insurance type. Base maps were created using the Stamen Designfrom Stadia Maps.

741 S1 Table. Generic medication names included in medication classes. The following generic

742 drug names recorded in the EHR during the study period were used for asthma and exacerbation

phenotyping as well as used as independent variables in select models (i.e., ICS). Instances in

which these drugs were listed as investigational or nasal formulations were not included.

S2 Table. Sources and spatiotemporal dimensions of geospatial datasets merged with EHR
data.

747 S3 Table. Asthma-related housing code violations extracted from the Philadelphia

748 Department of Licenses and Inspections.

749 S4 Table. Patient medications by exacerbation count levels. Shown are the number and

percentage of patients receiving each of the medication types listed according to their number of

751 exacerbations during the study period.

752 S5 Table. Characteristics of complete cases and patients excluded due to missingness.

753 Shown are the number and percentage of patients in each level for categorical variables and the

754 Median and Interquartile Range (IQR) for the Years followed variable in complete cases versus

those excluded due to missingness in the sex, ethnicity, health insurance type, BMI, and smokingstatus variables.

S6 Table. Adjusted Generalized Variance Inflation Factors (GVIFs) for each EHR and
SEDH variable included in the EHR & SEDH-adjusted negative binomial and logistic
regression models.

760 S7 Table. Individual-level asthma exacerbation risk factors in multivariable negative


binomial regression models. Shown are the adjusted incidence rate ratios (IRRs), 95%


762	confidence intervals	(CIs), and	p-values for neg	ative binomial	l models of asthma	a exacerbations as
-----	----------------------	------------	------------------	----------------	--------------------	--------------------

- a count outcome adjusted for EHR-derived variables only and for both EHR-derived and SEDH
- variables.


#### 765 S8 Table. Spatial GAMs of asthma exacerbations adjusted for individual risk factors that

- 766 most changed risk. Shown are the adjusted odds ratios (ORs), 95% confidence intervals (CIs),
- and p-values for spatial GAMs of asthma exacerbations as a dichotomous outcome adjusted for
- years followed and one-at-a-time for ADI, race, and health insurance type, the three variables
- whose percent reduction in variance of ORs was greater than 25.







### (C) EHR & SEDH-adjusted



# (A) ADI distribution



## (D) ADI-adjusted GAM



# (E) Race-adjusted GAM

medRxiv preprint doi: https://doi.org/10.1101/2024.10.24.24316063; this version posted October 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. Cheltenham Cheltenham Race Unknown/Other


White


Black

Medicare

Private

Medicaid








### (C) Health insurance type distribution




# (F) Health insurance typeadjusted GAM







# (C) ADI-adjusted GAM



# (D) Health insurance typeadjusted GAM

